Abstract
To the Editor.— Since the recent ban on the use of phenformin hydrochloride by the Food and Drug Administration, we have observed two major adverse drug reactions in patients being switched to tolazamide (Tolinase). Report of Cases.— Case1.—An 83-year-old man was previously treated with phenformin hydrochloride (DBI-TD), 50 mg orally three times a day for four years. Four days after changing to tolazamide, 250 mg orally three times a day, he came to the emergency room of the Medical Center Hospital of Vermont with a history of profuse diaphoresis, confusion, slurred speech, and severe shaking (possibly grand mal seizure, although verification is lacking). While being transported to the emergency room, rescue squad attendants gave the patient a glucose solution to drink. On arrival, the patient was oriented with irregular pulse of 88 beats per minute and blood pressure of 250/120 mm Hg. Monitoring by ECG showed frequent premature ventricular
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.